跳至主要内容
临床试验/NCT01122563
NCT01122563已完成不适用

Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 2: Responsiveness

Astellas Pharma Inc0 个研究点目标入组 55 人开始时间: 2009年9月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
55
主要终点
OABSS

研究概览

简要总结

This study is to evaluate change of overactive bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptoms OAB for 3 months or longer
  • At least 3 urgency episode in last 3 days
  • Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:
  • Number of micturition ≥8 times/day
  • Number of urgency episodes in 3 days ≥3

排除标准

  • Significant stress incontinence or mixed stress/urge incontinence
  • Subject with indwelling catheters or practicing intermittent self-catheterization
  • Symptomatic urinary tract infection, chronic inflammation
  • Diabetic neuropathy
  • Subjects who are prohibited from taking solifenacin as contraindications
  • Drug or non-drug treatment for OAB was started, quitted or changed in 4 weeks
  • Participation in any clinical trial in 30 days except for Part-1 of RESORT

结局指标

主要结局

OABSS

时间窗: Weeks 0, 4 and 12

次要结局

  • Quality of Life (QOL) Score(Weeks 0, 4 and 12)
  • Patient Perception of Bladder Condition (PPBC)(Weeks 0, 4 and 12)
  • International Prostate Symptom Score (IPSS)(Weeks 0, 4 and 12)

研究者

申办方类型
Industry

相似试验

A Study to Evaluate Response of Overactive Bladder... | 临床试验